Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRDLTSE:HLSCVE:RXTSE:WLLW On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRDLCardiol Therapeutics$1.52+9.1%$1.25$0.77▼$2.63$125.30M1.04308,989 shs368,415 shsHLSHLS TherapeuticsC$4.94+0.8%C$4.76C$3.00▼C$5.23C$109.90M1.0713,604 shs1,101 shsRXBioSyentC$11.75+0.4%C$11.49C$9.20▼C$12.13C$134.39M0.934,381 shs400 shsWLLWWillow BiosciencesC$0.30+11.1%C$0.07C$0.01▼C$0.15C$43.45M1.13626,457 shs166,614 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRDLCardiol Therapeutics+9.06%+3.13%+15.73%+87.16%-21.04%HLSHLS Therapeutics+1.87%+2.73%-2.00%+14.75%+34.25%RXBioSyent+0.43%+0.95%+1.03%+18.69%+17.50%WLLWWillow Biosciences0.00%+36.36%+900.00%+2,900.00%+160.87%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRDLCardiol Therapeutics2.0924 of 5 stars3.73.00.00.01.10.00.6HLSHLS Therapeutics0.4768 of 5 stars1.00.01.70.00.03.30.0RXBioSyentN/AN/AN/AN/AN/AN/AN/AN/AWLLWWillow BiosciencesN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRDLCardiol Therapeutics 3.33Buy$8.00427.70% UpsideHLSHLS Therapeutics 2.00HoldC$4.50-8.91% DownsideRXBioSyent 0.00N/AN/AN/AWLLWWillow Biosciences 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest WLLW, CRDL, RX, and HLS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/2/2025CRDLCardiol TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$9.004/16/2025CRDLCardiol TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.004/7/2025CRDLCardiol TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.00(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRDLCardiol TherapeuticsN/AN/AN/AN/A$0.22 per shareN/AHLSHLS TherapeuticsC$40.13M2.74C$0.32 per share15.22C$2.51 per share1.97RXBioSyentC$34.06M3.95C$3.82 per share3.07C$3.22 per share3.65WLLWWillow BiosciencesC$2.94M14.76C$0.36 per share0.83C$0.00 per share217.13Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRDLCardiol Therapeutics-$26.77M-$0.34N/AN/AN/AN/A-209.63%-141.09%7/14/2025 (Estimated)HLSHLS Therapeutics-C$15.53M-C$1.00N/A∞N/A-38.70%-25.27%-2.89%N/ARXBioSyentC$7.02MC$0.6219.07∞N/A20.60%20.01%12.86%N/AWLLWWillow Biosciences-C$7.92M-C$0.05N/A∞N/A-268.91%-602.73%-74.79%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRDLCardiol TherapeuticsN/AN/AN/AN/AN/AHLSHLS TherapeuticsC$0.204.05%N/AN/A N/ARXBioSyentC$0.181.53%N/A29.21%N/AWLLWWillow BiosciencesN/A7.35%N/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRDLCardiol Therapeutics0.013.263.26HLSHLS Therapeutics86.501.561.01RXBioSyent2.903.926.91WLLWWillow Biosciences902.050.8019.71Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRDLCardiol Therapeutics12.49%HLSHLS Therapeutics65.20%RXBioSyent1.37%WLLWWillow Biosciences0.10%Insider OwnershipCompanyInsider OwnershipCRDLCardiol Therapeutics5.25%HLSHLS Therapeutics0.37%RXBioSyent33.65%WLLWWillow Biosciences24.34%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRDLCardiol Therapeutics2082.65 million78.31 millionNot OptionableHLSHLS Therapeutics9122.25 millionN/ANot OptionableRXBioSyentN/A11.44 millionN/ANot OptionableWLLWWillow Biosciences19144.85 millionN/ANot OptionableWLLW, CRDL, RX, and HLS HeadlinesRecent News About These CompaniesWILLOW BIOSCIENCES INC. ANNOUNCES COMPLETION OF TRANSFORMATIVE RECAPITALIZATION TRANSACTIONS TO FORM ATLAS ENERGY CORP.June 19, 2025 | finance.yahoo.comWILLOW BIOSCIENCES INC. ANNOUNCES CONDITIONAL ACCEPTANCE OF TSX VENTURE EXCHANGE TO LIST PURSUANT TO THE TSXV SANDBOXJune 18, 2025 | stockhouse.comWillow Biosciences Inc.: Willow Biosciences Reports First Quarter 2025 Financial ResultsMay 13, 2025 | finanznachrichten.deWILLOW BIOSCIENCES INC. RECEIVES FIRM COMMITMENTS OF $30.0 MILLION UNDER PREVIOUSLY ANNOUNCED RECAPITALIZATION FINANCINGMay 9, 2025 | finance.yahoo.comWillow Biosciences Inc.: Willow Biosciences Announces Annual General And Special Meeting Voting ResultsApril 26, 2025 | finanznachrichten.deWillow Biosciences reports significant loss and imminent closureMarch 27, 2025 | msn.comWillow Biosciences to sell operating subsidiary Epimeron USA Inc.March 17, 2025 | msn.comWillow Biosciences to sell operating subsidiary for $3.38MMarch 17, 2025 | greenmarketreport.comGWILLOW ANNOUNCES SALE OF OPERATING SUBSIDIARYMarch 15, 2025 | finance.yahoo.comWillow Biosciences is looking for a buyerJanuary 21, 2025 | greenmarketreport.comGWILLOW ANNOUNCES CANCELLATION OF PREVIOUSLY ANNOUNCED NON-BROKERED OFFERING TO PURSUE LESS DILUTIVE ALTERNATIVESJanuary 2, 2025 | finance.yahoo.comWillow Biosciences Third Quarter 2024 Earnings: CA$0.01 loss per share (vs CA$0.018 loss in 3Q 2023)November 15, 2024 | finance.yahoo.comWillow Biosciences Inc.: Willow Biosciences Reports Third Quarter 2024 Financial Results And Provides Corporate UpdateNovember 12, 2024 | finanznachrichten.deWLLW:CA Willow Biosciences Inc.September 10, 2024 | seekingalpha.comCBG Producer Willow Biosciences Reports Record Q2 Revenue, Enters Major Pharma Deal Slated To Be Key Driver Of GrowthAugust 12, 2024 | benzinga.comWillow Biosciences Inc.August 9, 2024 | baystreet.caWILLOW BIOSCIENCES ANNOUNCES CLOSING OF PRIVATE PLACEMENT OF UNITSJuly 19, 2024 | finance.yahoo.comClosing Bell: Willow Biosciencesinc flat on Monday (WLLW)May 16, 2024 | theglobeandmail.comTSX:WLLW (Willow Biosciences Inc.)April 18, 2024 | fool.caWillow Biosciences Inc (WLLW)April 9, 2024 | investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir SoonIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseIntel's Turnaround Strategy Shifts From Planning to Attack ModeBy Jeffrey Neal Johnson | June 20, 2025View Intel's Turnaround Strategy Shifts From Planning to Attack Mode3 Stocks Getting Rare Double Upgrades From AnalystsBy Chris Markoch | June 6, 2025View 3 Stocks Getting Rare Double Upgrades From AnalystsWLLW, CRDL, RX, and HLS Company DescriptionsCardiol Therapeutics NASDAQ:CRDL$1.52 +0.13 (+9.06%) Closing price 07/3/2025 03:51 PM EasternExtended Trading$1.46 -0.06 (-3.96%) As of 07/3/2025 04:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.HLS Therapeutics TSE:HLSC$4.94 +0.04 (+0.82%) As of 10:55 AM EasternHLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada, the United States and the Rest of the world.BioSyent CVE:RXC$11.75 +0.05 (+0.43%) As of 07/3/2025 01:14 PM EasternBioSyent Inc., together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a natural health product to address polycystic ovarian syndrome symptoms; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by aging, menopause, stress, and chemotherapy; and Gelclair, a gel formulated to aid the pain or oral mucositis. In addition, the company provides Cathejell, a lubricant with anesthetic with the indication of lubricating and opening the urethra before the insertion of the catheter; Combogesic to manage mild to moderate acute pain and reduction of fever in adults; and Proktis-M, a rectal suppository for the healing of the anus and rectum. The company sells its products through wholesalers and retail pharmacy chains. The company was formerly known as Hedley Technologies Inc. and changed its name to BioSyent Inc. in June 2006. BioSyent Inc. was founded in 2006 and is headquartered in Mississauga, Canada.Willow Biosciences TSE:WLLWC$0.30 +0.03 (+11.11%) As of 06/27/2025Willow Biosciences Inc is a Canadian biotechnology company based in Calgary. It produces high purity, plant-derived compounds that provide building blocks for the global pharmaceutical, health and wellness, and consumer packaged goods industries. Geographically, it derives a majority of revenue from Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case How a Government Loan Changes the Game for Plug Power Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
